
Brentuximab vedotin

Printed from https://www.cancerquest.org/node/6429 on 03/28/2024

brentuximab vedotin 2D



Brand name: Adcetris®
IUPAC: (S)-citalopram 128196-01-0 [RN] 5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)
FDA approval: Yes
Enlace del fabricante
Usage:

As an infusion into a vein (intravenous, IV) over 30 minutes. The amount of Adcetris® that you will receive depends on many factors, including your weight, your general health or other health problems, and the type of cancer or condition you have. Your doctor will determine your exact dosage and schedule.

Mechanism:

Adcetris (brentuximab vedotin) is used to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma. It is an antibody-drug conjugate that combines an antibody and drug, allowing the antibody to direct the drug to a target on lymphoma cells known as CD30

Side effects:

The following side effects are common (occurring in greater than 30%) for patients taking Adcetris®: low blood counts, peripheral neuropathy(numbness and tingling of the hands and feet), fatigue (feeling tired or weak), nausea, diarrhea, fever, rash, upper respiratory infection, lung problems (if previously treated with bleomycin).

These are less common (occurring in 10-29%) side effects for patients receiving Adcetris®: vomiting, itching, cough, constipation, headache, shortness of breath, muscle or joint pain, difficulty sleeping, chills, dizziness, decreased appetite, hair loss, back pain/other pain, mild infusion reactions, peripher edema (swelling of ankles or feet), and hypersensitivity reaction may occur up to 24 hours after infusion.